Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 11c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.13), $0.11 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $3.68 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• UGI shares spike on reported KKR bid for the company
• Active options: NVDA TSLA AAPL INTC MU META SPCX AMZN NFLX AMD
• Clean Energy Fuels (CLNE) PT Lowered to $2.50 at Raymond James